Clinical trials of Herceptin® (trastuzumab)

European Journal of Cancer

Volumn 37, Issue SUPPL. 1, 2001, Pages 18-24

  Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Efficacy; Herceptin (trastuzumab); Metastatic breast cancer; Survival

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEART DISEASE; HEART VENTRICLE ARRHYTHMIA; HUMAN; METASTASIS; NAUSEA; PRIORITY JOURNAL; VOMITING;

EID: 0035125614     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(00)00404-4     Document Type: Article

References (18)

1. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
2. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
3. Differential responses of human tumor cell lines to anti-HER2 monoclonal antibodies
4. HER2 antibody for human cancer therapy
5. Development and characterization of a rhuMAb HER2 antibody assay for clinical evaluation of cytotoxic potency
6. Antibody dependant cell-mediated cytotoxicity in breast cancer patients in phase II clinical trials of a humanized anti-HER2 antibody
7. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
8. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
9. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
10. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product
11. Overview of the trastuzumab (Herceptin®) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
12. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
13. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
14. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
15. First-line, single-agent Herceptin® in metastatic breast cancer
16. Addition of Herceptin® (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial
17. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin® (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
18. Testing for erbB-2 by immunohistochemistry in breast cancer